{"id":"W2902172836","doi":"10.1021/acs.jmedchem.8b00843","title":"The Journey of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) from Lab to Clinic","year":2018,"lang":"en","type":"article","venue":"Journal of Medicinal Chemistry","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":184,"is_retracted":false,"has_abstract":true,"ca_institutions":"Merck Canada Inc. (Canada)","funders":"National Institute of Allergy and Infectious Diseases; Government of Shandong Province; Science and Engineering Research Board; National Institutes of Health; Uppsala Universitet; National Natural Science Foundation of China; Department of Science and Technology, Ministry of Science and Technology, India; National Institute of Mental Health; European Molecular Biology Laboratory; Shandong University; Villum Fonden","keywords":"Efavirenz; Etravirine; Nevirapine; Rilpivirine; Reverse transcriptase; Reverse-transcriptase inhibitor; Nucleoside Reverse Transcriptase Inhibitor; Virology; Human immunodeficiency virus (HIV); Chemistry; Pharmacology; Medicine; Antiretroviral therapy; Viral load; RNA","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0008965518,0.0002090173,0.0005684622,0.0000686643,0.0001144222,0.00001380029,0.0002489398,0.0001247471,0.0009777081],"category_scores_gemma":[0.0005013231,0.0001262688,0.0002554702,0.0002199333,0.000244615,0.00007036146,0.00003373271,0.000491603,0.00009644675],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000146522,"about_ca_system_score_gemma":0.0004885425,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00001608615,"about_ca_topic_score_gemma":0.000005314795,"domain_scores_codex":[0.9975888,0.00003528889,0.001090107,0.0001748586,0.0008314296,0.0002794995],"domain_scores_gemma":[0.9979718,0.0002007033,0.0005413717,0.0002975838,0.0004557669,0.0005327708],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.003023227,0.0005211196,0.02117399,0.0001620784,0.0009904788,0.001054695,0.004342289,5.77119e-7,0.3262272,0.000001499463,0.6338523,0.008650517],"study_design_scores_gemma":[0.008861384,0.001068142,0.009551446,0.003182541,0.001240158,0.0008286114,0.005678506,0.0000162572,0.7166634,0.00009923813,0.2525426,0.0002676571],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9741297,0.0008998155,0.0001044632,0.02008462,0.0006016589,0.0001518261,0.00002006995,0.000008960207,0.003998849],"genre_scores_gemma":[0.9830872,0.000430643,0.002046358,0.0006872874,0.002515489,0.000003084936,0.00001087645,0.00002797449,0.01119106],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3904363,"threshold_uncertainty_score":0.9999355,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01457388499241907,"score_gpt":0.2861052684949563,"score_spread":0.2715313835025372,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}